Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes

Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes. Liu, Z., Yu, D., Song, H., Postings, M. L., Scott, P., Wang, Z., Ren, J., & Qu, X. ACS NANO, 17(9):8141–8152, May, 2023.
doi abstract bibtex

Targeted protein degradation has demonstrated the power to modulate protein homeostasis. For overcoming the limitation to intracellular protein degradation, lysosome targeting chimeras have been recently developed and successfully utilized to degrade a range of disease-relevant extracellular and membrane proteins. Inspired by this strategy, here we describe our proof-of-concept studies using metallohelix-based degraders to deliver the extracellular human islet amyloid polypeptide (hIAPP) into the lysosomes for degradation. Our designed metallohelix can bind and inhibit hIAPP aggregation, and the conjugated tri-GalNAc motif can target macrophage galactose-type lectin 1 (MGL1), yielding chimeric molecules that can both inhibit hIAPP aggregation and direct the bound hIAPP for lysosomal degradation in macrophages. Further studies demonstrate that the enhanced hIAPP clearance has been through the endolysosomal system and depends on MGL1-mediated endocytosis. Intriguingly, ? enantiomers show even better efficiency in preventing hIAPP aggregation and promoting internalization and degradation of hIAPP than Delta enantiomers. Moreover, metallohelix-based degraders also faciltate the clearance of hIAPP through asialoglycoprotein receptor in liver cells. Overall, our studies demonstrate that chiral metallohelix can be employed for targeted degradation of extracellular misfolded proteins and possess enantioselectivity.

@article{liu_enantioselective_2023,
	title = {Enantioselective {Degrader} for {Elimination} of {Extracellular} {Aggregation}-{Prone} {Proteins} {hIAPP} {Associated} with {Type} 2 {Diabetes}},
	volume = {17},
	issn = {1936-0851},
	doi = {10.1021/acsnano.2c11476},
	abstract = {Targeted protein degradation has demonstrated the power to modulate protein homeostasis. For overcoming the limitation to intracellular protein degradation, lysosome targeting chimeras have been recently developed and successfully utilized to degrade a range of disease-relevant extracellular and membrane proteins. Inspired by this strategy, here we describe our proof-of-concept studies using metallohelix-based degraders to deliver the extracellular human islet amyloid polypeptide (hIAPP) into the lysosomes for degradation. Our designed metallohelix can bind and inhibit hIAPP aggregation, and the conjugated tri-GalNAc motif can target macrophage galactose-type lectin 1 (MGL1), yielding chimeric molecules that can both inhibit hIAPP aggregation and direct the bound hIAPP for lysosomal degradation in macrophages. Further studies demonstrate that the enhanced hIAPP clearance has been through the endolysosomal system and depends on MGL1-mediated endocytosis. Intriguingly, ? enantiomers show even better efficiency in preventing hIAPP aggregation and promoting internalization and degradation of hIAPP than Delta enantiomers. Moreover, metallohelix-based degraders also faciltate the clearance of hIAPP through asialoglycoprotein receptor in liver cells. Overall, our studies demonstrate that chiral metallohelix can be employed for targeted degradation of extracellular misfolded proteins and possess enantioselectivity.},
	number = {9},
	urldate = {2023-04-30},
	journal = {ACS NANO},
	author = {Liu, Zhenqi and Yu, Dongqin and Song, Hualong and Postings, Miles Lewis and Scott, Peter and Wang, Zhao and Ren, Jinsong and Qu, Xiaogang},
	month = may,
	year = {2023},
	pages = {8141--8152},
}

Downloads: 0

{"_id":"5E7JEeEEqoJ7RYsek","bibbaseid":"liu-yu-song-postings-scott-wang-ren-qu-enantioselectivedegraderforeliminationofextracellularaggregationproneproteinshiappassociatedwithtype2diabetes-2023","author_short":["Liu, Z.","Yu, D.","Song, H.","Postings, M. L.","Scott, P.","Wang, Z.","Ren, J.","Qu, X."],"bibdata":{"bibtype":"article","type":"article","title":"Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes","volume":"17","issn":"1936-0851","doi":"10.1021/acsnano.2c11476","abstract":"Targeted protein degradation has demonstrated the power to modulate protein homeostasis. For overcoming the limitation to intracellular protein degradation, lysosome targeting chimeras have been recently developed and successfully utilized to degrade a range of disease-relevant extracellular and membrane proteins. Inspired by this strategy, here we describe our proof-of-concept studies using metallohelix-based degraders to deliver the extracellular human islet amyloid polypeptide (hIAPP) into the lysosomes for degradation. Our designed metallohelix can bind and inhibit hIAPP aggregation, and the conjugated tri-GalNAc motif can target macrophage galactose-type lectin 1 (MGL1), yielding chimeric molecules that can both inhibit hIAPP aggregation and direct the bound hIAPP for lysosomal degradation in macrophages. Further studies demonstrate that the enhanced hIAPP clearance has been through the endolysosomal system and depends on MGL1-mediated endocytosis. Intriguingly, ? enantiomers show even better efficiency in preventing hIAPP aggregation and promoting internalization and degradation of hIAPP than Delta enantiomers. Moreover, metallohelix-based degraders also faciltate the clearance of hIAPP through asialoglycoprotein receptor in liver cells. Overall, our studies demonstrate that chiral metallohelix can be employed for targeted degradation of extracellular misfolded proteins and possess enantioselectivity.","number":"9","urldate":"2023-04-30","journal":"ACS NANO","author":[{"propositions":[],"lastnames":["Liu"],"firstnames":["Zhenqi"],"suffixes":[]},{"propositions":[],"lastnames":["Yu"],"firstnames":["Dongqin"],"suffixes":[]},{"propositions":[],"lastnames":["Song"],"firstnames":["Hualong"],"suffixes":[]},{"propositions":[],"lastnames":["Postings"],"firstnames":["Miles","Lewis"],"suffixes":[]},{"propositions":[],"lastnames":["Scott"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Wang"],"firstnames":["Zhao"],"suffixes":[]},{"propositions":[],"lastnames":["Ren"],"firstnames":["Jinsong"],"suffixes":[]},{"propositions":[],"lastnames":["Qu"],"firstnames":["Xiaogang"],"suffixes":[]}],"month":"May","year":"2023","pages":"8141–8152","bibtex":"@article{liu_enantioselective_2023,\n\ttitle = {Enantioselective {Degrader} for {Elimination} of {Extracellular} {Aggregation}-{Prone} {Proteins} {hIAPP} {Associated} with {Type} 2 {Diabetes}},\n\tvolume = {17},\n\tissn = {1936-0851},\n\tdoi = {10.1021/acsnano.2c11476},\n\tabstract = {Targeted protein degradation has demonstrated the power to modulate protein homeostasis. For overcoming the limitation to intracellular protein degradation, lysosome targeting chimeras have been recently developed and successfully utilized to degrade a range of disease-relevant extracellular and membrane proteins. Inspired by this strategy, here we describe our proof-of-concept studies using metallohelix-based degraders to deliver the extracellular human islet amyloid polypeptide (hIAPP) into the lysosomes for degradation. Our designed metallohelix can bind and inhibit hIAPP aggregation, and the conjugated tri-GalNAc motif can target macrophage galactose-type lectin 1 (MGL1), yielding chimeric molecules that can both inhibit hIAPP aggregation and direct the bound hIAPP for lysosomal degradation in macrophages. Further studies demonstrate that the enhanced hIAPP clearance has been through the endolysosomal system and depends on MGL1-mediated endocytosis. Intriguingly, ? enantiomers show even better efficiency in preventing hIAPP aggregation and promoting internalization and degradation of hIAPP than Delta enantiomers. Moreover, metallohelix-based degraders also faciltate the clearance of hIAPP through asialoglycoprotein receptor in liver cells. Overall, our studies demonstrate that chiral metallohelix can be employed for targeted degradation of extracellular misfolded proteins and possess enantioselectivity.},\n\tnumber = {9},\n\turldate = {2023-04-30},\n\tjournal = {ACS NANO},\n\tauthor = {Liu, Zhenqi and Yu, Dongqin and Song, Hualong and Postings, Miles Lewis and Scott, Peter and Wang, Zhao and Ren, Jinsong and Qu, Xiaogang},\n\tmonth = may,\n\tyear = {2023},\n\tpages = {8141--8152},\n}\n\n","author_short":["Liu, Z.","Yu, D.","Song, H.","Postings, M. L.","Scott, P.","Wang, Z.","Ren, J.","Qu, X."],"key":"liu_enantioselective_2023","id":"liu_enantioselective_2023","bibbaseid":"liu-yu-song-postings-scott-wang-ren-qu-enantioselectivedegraderforeliminationofextracellularaggregationproneproteinshiappassociatedwithtype2diabetes-2023","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://warwick.ac.uk/fac/cross_fac/wesic/research/wpg/research/WPGsep2024.bib","dataSources":["m4fxWT6XKrYfGbZFR","GBhqMC9hjyD5vqptk","6idaYK6okJY39mWgG"],"keywords":[],"search_terms":["enantioselective","degrader","elimination","extracellular","aggregation","prone","proteins","hiapp","associated","type","diabetes","liu","yu","song","postings","scott","wang","ren","qu"],"title":"Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes","year":2023}